Bio-Thera’s BAT2206 is approved to treat moderate to severe plaque psoriasis patients aged six years or above. Credit: Ternavskaia Olga Alibec via shutterstock.com.

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar.

Biomm will gain exclusive rights for the distribution and marketing in Brazil of the proposed biosimilar to Janssen’s Stelara.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bio-Thera will handle BAT2206’s global development and commercial supply out of its manufacturing plants in Guangzhou, China.

In 2020, both companies initially collaborated for Biomm’s distribution and marketing of Bio-Thera’s bevacizumab biosimilar, BAT1706, in Brazil.

BAT2206 is approved in the country to treat active psoriatic arthritis (PsA) in adults, either as a monotherapy or along with methotrexate.

See Also:

It has also been approved for the treatment of moderate to severe PsA in patients aged six years or above and adult patients with moderate to severe active Crohn’s disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The therapy, which completed a Phase I trial, is now being assessed in an international Phase III clinical trial that includes participants from China and Eastern European countries.

Bio-Thera CEO Dr Shengfeng Li stated: “Bio-Thera is pleased to expand our partnership with Biomm to commercialise our ustekinumab biosimilar programme in Brazil.

“By expanding our partnership with Biomm, Bio-Thera is doubling its commitment to providing Brazilian patients with increased access to important biotherapeutics at affordable prices.”

The company stated that the collaboration will use the local presence, sales and marketing capabilities of Biomm in Brazil.

It plans to seek regulatory approval from the European Medicines Agency, the China National Medical Products Administration and the US Food and Drug Administration.

Biomm will also be responsible for filing for BAT2206’s regulatory approval in Brazil.